Carnitine for the Treatment of Fatigue in Multiple Sclerosis

comparison of Carnitine with placebo for the Treatment of Fatigue in Patients with Multiple Sclerosis in a Randomized Double-blind Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012092010891N1

Enrollment

Registered

2014-12-23

Start date

2011-06-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis. Multiple sclerosis

Interventions

Intervention 1: intervention group: carnitine 1000mg/d for 8 weeks (tab 500mg, bid). Intervention 2: control: placebo for 8 weeks.

Treatment - Drugs

intervention group: carnitine 1000mg/d for 8 weeks (tab 500mg, bid)

control: placebo for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: definite relapsing-remitting MS according to McDonald’s criteria? age between18 and 50 years; Expanded Disability Status Scale (EDSS) less than 4.0; MS related fatigue with a Fatigue Severity Scale (FSS)>4; receiving interferon ß therapy for at least one year Exclusion Criteria: symptoms of depression (Beck Depression Criteria-pc>5); relapse within previous 8 weeks; had received corticosteroids within previous 8 weeks; had received medications affecting MS related fatigue

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Decrease of fatigue(FSS). Timepoint: week 4 and 8. Method of measurement: FSS score.	—

Secondary

Measure	Time frame
Drug side effects. Timepoint: 4,8 weeks. Method of measurement: recall.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFereshteh Ashtari, Neurologist

Isfahan Medical School

f_ashtari@med.mui.ac.ir+98 31 1235 0094

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026